Skip to main navigation

Careers    |    Contact    |    News    |   

  • About Arbutus
    • Overview
    • Management
    • Our Board
    • Scientific Advisory Board
    • Careers
  • About HBV
    • HBV Background
    • HBV Science
    • The Baruch S. Blumberg Institute
  • >
  • R&D Portfolio
    • HBV Assets
      • AB-729 (GalNAc-RNAi)
      • AB-836 (Oral Capsid Inhibitor)
      • AB-101 (Oral PD-L1 Inhibitor)
      • AB-161 (Oral HBV RNA Destabilizers)
    • Coronavirus
  • Partners
    • Partnering & Licensing
    • Collaborations & Partners
  • Investors
    • Investor Center
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Investor FAQ
    • Contact Us

Investor Relations

  • Investor Center
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Press Releases
  • Events & Presentations
  • Investor FAQ
  • Contact Us

SEC Filing Details

Document Details

Form
8-K
Filing Date
May 24, 2022
Document Date
May 24, 2022
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Arbutus Biopharma Corporation
Issuer
ARBUTUS BIOPHARMA CORP

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.LAB - XBRL LABEL FILE
EX-101.PRE - XBRL PRESENTATION FILE
XML - XBRL INSTANCE DOCUMENT

Shareholder Tools

  • Email Alerts Email Alerts
  • RSS News Feeds RSS News Feeds
  • Download Library Download Library

© 2022 Arbutus Biopharma

Legal Terms